The genetic technology similar to the vaccine formulation methods used by the Pfizer-BioNTech and Moderna alliances for Covid-19 could help treat heart attack patients.
This is the result of a groundbreaking study recently conducted.
Using mRNA technology, the technology behind the Covid-19 vaccine, King’s College London has identified genetic codes responsible for producing proteins that stimulate heart cell production, paving the way for the first treatment approach for heart attack patients.
mRNA technology may help stimulate heart cell production. (Photo: PAHO).
The lead researcher, Professor Mauro Giacca, stated that the number of heart muscle cells at the time of birth is the same as the number at the time of death.
After a heart attack, the heart lacks the ability to heal or regenerate itself. Therefore, the research team’s goal is to discover a therapy that stimulates heart cells to replicate, multiply, and regenerate this organ.
“We are using the vaccine formulation technology from Pfizer and Moderna to inject mRNA proteins into the heart, delivering them to the remaining cells and promoting cell self-production. The new cells will replace the dead cells,” Professor Giacca explained.
Additionally, researchers are very excited about the potential to limit damage to the heart once a heart attack occurs. Theoretically, if proteins are injected when the ambulance arrives, patients may experience reduced severity and thus avoid the risk of death.
Clinical trials on humans are expected to begin in two years.
In the United States alone, approximately 805,000 people experience heart attacks each year, while in the United Kingdom, the number is about 100,000.
